Natco Pharma Ltd has got the final approval for Abbreviated New Drug Application (ANDA) from the US Food and Drug Administration (FDA) for the generic version of Vidaza (Azacitidine for injection, 100 mg per vial), single-dose vial.
According to a company statement, Natco and its marketing partner Breckenridge Pharmaceutical, Inc. (BPI) plan to launch the product in the US market in the near future.
Vidaza by Celgene Corporation is a prescription anti-cancer chemotherapy drug that is indicated to treat, myelodysplastic syndrome (MDS).
Vidaza generated total combined sales of $188 million for the 12-month period ended April 2017, based on industry sales data.
Natco shares ended the session down by 0.74 per cent at Rs 965.30 on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.